# Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

> **NCT00636168** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1211 (actual)

## Conditions studied

- High Risk Stage III Melanoma

## Interventions

- **DRUG:** ipilimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00636168
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-30
- **Primary completion:** 2013-07-26
- **Final completion:** 2018-11-26
- **Target enrollment:** 1211 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636168, "Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00636168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*